ClinicalTrials.gg
RecruitingNCT07427511SNR-HDHIUpdated Mar 10, 2026

SwissNeuroRehab - HDHI

An interventional study of Device assisted high-dose therapy in Stroke, sponsored by Centre Hospitalier Universitaire Vaudois. Recruiting at 5 sites in Switzerland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Centre Hospitalier Universitaire Vaudois · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.

Planned enrollment
59th of 147
120 · median 79
Started
2026
with 11 others
No phase
95 of 216
24 open now
Primary completion
2028-05
later than 38 of 59 live
Registered
202nd of 216
by date
Lead sponsor
4 of 216
Centre Hospitalier Universitaire Vaudois

Among the 216 studies in Stroke with a site in Switzerland, this one is the 59th largest by planned enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2026, is one of 95 with no phase, reaches primary completion later than 38 of the 59 other live ones, and was the 202nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Stroke with a site in Switzerland, or all of them as a file.
02

Study summary

High-dose, high-intensity (HDHI) neurorehabilitation has shown promise for improving functional outcomes after acquired brain injury (ABI), yet its feasibility and impact across different stages of care and real-world clinical settings remain insufficiently understood.

The SwissNeuroRehab (SNR) initiative, bringing together Swiss rehabilitation centres to develop and evaluate innovative, technology-supported models of neurorehabilitation, provides the broader framework within which this study is conducted.

Within this framework, a structured HDHI therapy pathway supported by CE-marked digital neurorehabilitation tools has been developed for delivery across inpatient, outpatient, and home environments in Switzerland.

This multicentre, non-randomised interventional feasibility study evaluates the feasibility and preliminary clinical effects of implementing this HDHI rehabilitation pathway for adults with stroke in subacute and chronic stages. Participants will receive approximately 300 minutes per week of active, technology-supported training in addition to standard rehabilitation care, following an individually tailored pathway across settings. Standardised clinical assessments, patient-reported outcomes, documentation of rehabilitation procedures, and socioeconomic measures will be collected at baseline, discharge, and follow-up timepoints up to 12-15 months post-enrollment.

The primary aim of the study is to assess the feasibility of the HDHI intervention within routine rehabilitation workflows across multiple Swiss centres. Feasibility will be evaluated through (i) adherence to at least half of the weekly 300-minute Active Training Time target and (ii) patients' perceived feasibility and satisfaction with the program.

Secondary aims are to explore preliminary clinical and functional changes, patient-reported outcomes, and quantify socioeconomic impacts through dedicated surveys and cost data.

Findings from this study will (i) determine whether a structured HDHI rehabilitation pathway can be feasibly implemented across diverse clinical contexts, (ii) provide initial estimates of clinical and socioeconomic outcomes to support planning of future controlled trials.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • high dose
  • intensive therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-85 years.
  • Confirmed diagnosis of stroke (ischemic or hemorrhagic) >7 days ago
  • Be able to sit unassisted
  • Able and willing to give
  • Have motor difficulties of the Upper Extremity and/or Lower Extremity
  • Willing to commit to program length \& daily training dose
  • Willing to have assessments at start and end of program
  • Signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment
  • Uncontrolled seizure disorder or epilepsy - clinician's judgement)
  • Any medical condition that would compromise their safety (inability to communicate, vision or hearing impairment, heart condition that limits participation in exercise) and tolerability (cardiac )
  • Pain that would limit rehabilitation dose
  • Severe apraxia
  • Severe memory disorder
  • Severe hemispatial neglect
  • Plegia of the affected limb
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Device assisted high-dose therapy

    Participants receive a high-dose, high-intensity (HDHI) motor rehabilitation program supported by digital therapeutic devices, delivered across inpatient, outpatient and home-based settings.

    Behavioral: Device assisted high-dose therapy

Interventions

  • BehavioralDevice assisted high-dose therapy

    Participants undergo a high-dose, high-intensity (HDHI) neurorehabilitation program using CE-marked digital therapeutic devices (MindMotion GO, Izar). The intervention is tailored to individual motor rehabilitation needs and delivered across settings: during inpatient rehabilitation (4-6 weeks) and/or home-based outpatient care (8-12 weeks). Participants are expected to train actively for approximately one hour per day (5day week), supported by clinical staff and if applicable, caregivers.The intervention is supervised by clinical teams specifically trained in the HDHI protocol, who provide ongoing therapeutic support and monitor progress across settings.

    Also known as: Device assisted high-dose neurorehabilitation

06

What researchers measure

Primary outcomes

  1. HDHI training adherence (Active Training Time, ATT)

    The adherence to ≥150 minutes per week of Active Training Time (ATT), corresponding to at least half of the predefined weekly target of 300 minutes/week. ATT is derived from device-recorded active training logs and aggregated by calendar week during the intervention period. Weekly ATT is summarized across the intervention period to determine whether participants meet the predefined weekly adherence criterion.

    Time frame: Weekly during the intervention period (up to 18 weeks)

  2. Feasibility and satisfaction with the HDHI program (Program Feasibility and Satisfaction Questionnaire)

    The perceived feasibility and patient satisfaction with the HDHI program, assessed using a study-specific Program Feasibility and Satisfaction Questionnaire consisting of 12 Likert-scale items covering accessibility/ease of use, pleasant content, empowerment capability, self-efficacy, alignment with clinical objectives, alignment with personal values and culture, environmental context, trust in the program, and perceived personal value. Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). A total score is calculated by summing item scores, with a minimum possible score of 12 and a maximum possible score of 60; higher scores indicate greater perceived feasibility and satisfaction.

    Time frame: At discharge from the intervention and at follow-up assessments up to 15 months post-inclusion

Secondary outcomes

  1. Fugl-Meyer Assessment - Upper Extremity (FMA-UE)

    Upper-limb motor impairment measured using the Fugl-Meyer Assessment for Upper Extremity (FMA-UE). The motor domain of the FMA-UE consists of 33 items assessing upper-limb motor function, with a total score ranging from 0 to 66; higher scores indicate better motor function and less motor impairment.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  2. Action Research Arm Test (ARAT)

    Upper-limb functional performance measured using the Action Research Arm Test (ARAT). The ARAT consists of 19 items across grasp, grip, pinch, and gross movement domains, with each item scored from 0 to 3, resulting in a total score ranging from 0 to 57; higher scores indicate better upper-limb functional performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  3. Extended Barthel Index (eBI)

    Activities of daily living performance measured using the Extended Barthel Index (eBI). The eBI assesses functional independence in activities of daily living using a 16-item scale, with a total score ranging from 0 to 64; higher scores indicate greater independence and better activities of daily living performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  4. Functional Independence Measure (FIM)

    Functional independence measured using the Functional Independence Measure (FIM). The FIM is an 18-item scale assessing independence in activities of daily living, with each item scored from 1 to 7, resulting in a total score ranging from 18 to 126; higher scores indicate greater functional independence.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  5. Modified Rankin Scale (mRS)

    Global disability measured using the Modified Rankin Scale (mRS). The mRS is a 7-point ordinal scale ranging from 0 (no symptoms) to 6 (death), used to assess the level of functional disability and dependence in daily activities; higher scores indicate greater disability and worse functional outcome.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  6. Grip Strength - Hand Dynamometry

    Grip strength of the affected hand measured using a Jamar hand dynamometer. Maximum voluntary grip strength is recorded in kilograms (kg), calculated as the mean of three trials; higher values indicate greater grip strength.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  7. Mini Balance Evaluation Systems Test (Mini-BESTest)

    Balance performance measured using the Mini Balance Evaluation Systems Test (Mini-BESTest). The Mini-BESTest consists of 14 items, each scored from 0 to 2, assessing dynamic balance across anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait, with a total score ranging from 0 to 28; higher scores indicate better balance performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  8. 10-Meter Walk Test (10mWT)

    Gait speed measured using the 10-Meter Walk Test (10mWT) performed at self-selected walking speed. Gait speed is calculated in meters per second (m/s); higher values indicate faster walking speed and better gait performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  9. 6-Minute Walk Test (6MWT)

    Gait endurance measured using the 6-Minute Walk Test (6MWT). Endurance is quantified as the total distance walked in meters during the 6-minute test period; higher values indicate greater walking endurance and better gait performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  10. Timed Up and Go test (TUG)

    Functional mobility measured using the Timed Up and Go test (TUG). Performance is quantified as the time required to stand up from a chair, walk 3 meters, turn, walk back, and sit down, measured in seconds (s); lower values indicate better functional mobility.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  11. Five Times Sit-to-Stand test (5xSTS)

    Lower-limb functional strength and balance measured using the Five Times Sit-to-Stand test (5xSTS). Performance is quantified as the time required to stand up from and sit down on a chair five times consecutively, measured in seconds (s); lower values indicate better lower-limb functional performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

Other outcomes

  1. Patient Global Impression of Change (PGIC)

    Participant's global perception of change in overall health status measured using the Patient Global Impression of Change (PGIC) scale. The PGIC is a 7-point ordinal scale ranging from 1 (very much worse) to 7 (very much improved); higher scores indicate greater perceived improvement.

    Time frame: At discharge from the intervention and at follow-up assessments up to 15 months post-inclusion

  2. Pain Visual Analog Scale (VAS)

    Self-reported pain intensity measured using a Visual Analog Scale (VAS). Pain intensity is rated on a numeric scale ranging from 0 (no pain) to 100 (worst pain imaginable); higher scores indicate greater pain intensity.

    Time frame: From baseline to follow-up assessments up to 12 months post-discharge

  3. EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)

    Health-related quality of life measured using the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire. The EQ-5D-5L descriptive system assesses health status across five dimensions, each rated on five ordered levels (1 = no problems to 5 = extreme problems). Responses are combined to derive an EQ-5D-5L index score; higher index values indicate better health-related quality of life.

    Time frame: From baseline to follow-up assessments up to 12 months post-discharge

  4. PROMIS Global-10

    Self-reported global physical and mental health status measured using the PROMIS Global Health (Global-10) questionnaire. The instrument yields two summary scores: Global Physical Health (GPH) raw score and Global Mental Health (GMH) raw score. Each summary score has a raw score range from 4 to 20; higher scores indicate better health status.

    Time frame: From baseline to follow-up assessments up to 12 months post-discharge

  5. Short Form Stroke Impact Scale (SF-SIS)

    Stroke-specific impact on daily life and participation measured using the Short Form Stroke Impact Scale (SF-SIS). The SF-SIS is a patient-reported questionnaire assessing the perceived impact of stroke on physical function, activities, cognition, communication, emotion, and participation using ordered response categories; higher scores indicate better function and less perceived impact of stroke.

    Time frame: From baseline to follow-up assessments up to 12 months post-discharge

  6. Falls and sleep-related outcomes (modified questionnaire)

    Self-reported occurrence of falls and sleep-related characteristics assessed using a study-specific modified falls and sleep questionnaire. Falls outcomes include the number of falls, number of falls resulting in injury, and number of falls requiring hospitalisation during the preceding month. Sleep-related outcomes include self-reported interference of sleep problems with daily functioning, assessed using an ordinal response scale, where higher ratings indicate greater interference.

    Time frame: From baseline to follow-up assessments up to 12 months post-discharge

  7. Behavioral Risk Factor Surveillance System (BRFSS) items

    Health-related risk and well-being characteristics assessed using selected items from the Behavioral Risk Factor Surveillance System (BRFSS). Outcomes include the number of days in the past 30 days during which participants report poor physical health, poor mental health, and activity limitation due to poor physical or mental health, recorded as counts of days (0-30). Higher values indicate a greater number of unhealthy days.

    Time frame: From baseline to follow-up assessments up to 12 months post-discharge

  8. Socio-Economic Status and Health Resource Use

    Socio-economic characteristics and health resource use assessed using a study-specific structured socio-economic questionnaire and rehabilitation-related resource use data. Variables include employment status, living situation, support needs, and use of rehabilitation and healthcare services, reported descriptively.

    Time frame: Socio-economic questionnaire: From baseline to follow-up assessments up to 15 months post-inclusion Administrative health resource use data: Annually, for the duration of study participation

  9. Standard of Care and Exercise Exposure

    Exposure to standard rehabilitation care and additional physical exercise assessed using a study-specific structured questionnaire and/or exercise diary. Variables include the type, frequency, and duration of rehabilitation and physical activities performed outside the HDHI program, reported descriptively.

    Time frame: During study participation, assessed retrospectively at discharge and follow-up assessments up to 15 months post-inclusion

  10. Program delivery feasibility

    Feasibility of HDHI program delivery assessed using program-specific documentation, including enrollment records, completion status, and discharge documentation. Feasibility outcomes include the number and proportion of participants who initiate the program, complete the intervention, and discontinue prematurely, reported descriptively.

    Time frame: From program initiation through completion of the intervention (up to 18 weeks)

  11. Training dose delivery

    Training dose delivery assessed using device-recorded session logs. Outcomes include total active training time, number of completed sessions, and distribution of training across modalities, summarized descriptively over the intervention period.

    Time frame: During the intervention period (up to 18 weeks)

  12. Systolic Blood Pressure

    Systolic blood pressure measured in millimeters of mercury (mmHg) using standard clinical procedures.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion.

  13. Diastolic blood pressure

    Diastolic blood pressure measured in millimeters of mercury (mmHg) using standard clinical procedures.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  14. Heart Rate

    Heart rate measured in beats per minute (bpm) using standard clinical procedures.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  15. Peripheral oxygen saturation (SpO₂)

    Peripheral oxygen saturation measured as percentage of hemoglobin oxygen saturation (%) using pulse oximetry.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  16. Digit Span Forward

    Memory domain: Verbal short-term memory and attention span, assessed using the Digit Span Forward task. Performance is defined as the maximum correctly recalled digit sequence length; Performance is reported as a standardized score derived from test norms (e.g., T-score).

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  17. Digit Span Backward

    Working memory domain: Verbal working memory involving mental manipulation, assessed using the Digit Span Backward task. Performance is reported as a standardized score derived from test norms (e.g., T-score), with higher scores indicating better working memory performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  18. Block Span (Corsi Block-Tapping Test)

    Memory domain: Visuospatial short-term memory, assessed using the Block Span (Corsi Block-Tapping) Test. Performance is reported as a standardized score based on normative data, with higher scores indicating better visuospatial working memory.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  19. Trail Making Test Part A (TMT-A)

    Non-lateralized attention (processing speed domain): visual scanning and psychomotor processing speed assessed using the Trail Making Test Part A. Performance is reported using standardized scores based on completion time, with higher scores indicating better performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  20. Trail Making Test Part B(TMT-B)

    Executive function domain: cognitive flexibility and set shifting assessed using the Trail Making Test Part B under speeded visuomotor conditions. Performance is reported using standardized scores, with higher scores indicating better cognitive flexibility.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  21. Color Trails Test 1

    Non-lateralized attention (processing speed domain): visual scanning and psychomotor processing speed assessed using the Color Trails Test Part 1. The Color Trails Test is used as a language-reduced alternative to the Trail Making Test Part A in participants with aphasia or limited literacy. Performance is reported as a standardized score derived from test norms, with higher scores indicating better performance.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  22. Color Trails Test 2

    Executive function domain: cognitive flexibility and set shifting assessed using the Color Trails Test Part 2 under speeded visuomotor conditions. The Color Trails Test is used as a language-reduced alternative to the Trail Making Test Part B in participants with aphasia or limited literacy. Performance is reported as a standardized score derived from test norms, with higher scores indicating better cognitive flexibility.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  23. Five-Point Test (5PT)

    Executive function domain: figural fluency assessed using the Five-Point Test, reflecting nonverbal generative fluency and self-monitoring. Performance is reported as a standardized score derived from the number of unique designs produced, with higher scores indicating better figural fluency.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  24. Phonemic Fluency

    Executive function domain: phonemic verbal fluency assessed by the ability to generate words according to phonemic constraints within a fixed time period. Performance reflects executive control of lexical retrieval and self-monitoring and is reported as a standardized score, with higher scores indicating better phonemic fluency.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  25. Semantic Fluency

    Executive function domain: semantic verbal fluency assessed by the ability to generate words within a semantic category during a fixed time period. Performance primarily reflects semantic memory retrieval supported by executive control processes and is reported as a standardized score, with higher scores indicating better semantic fluency.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  26. Stroop Test

    Executive function domain: interference control assessed using the Stroop Color-Word Test. Performance reflects the ability to resolve cognitive interference under competing stimulus conditions and is reported as a standardized score derived from response time and error measures, with higher scores indicating better interference control.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  27. TAP Go/No-Go

    Executive function domain: motor response inhibition assessed using the Go/No-Go subtest of the Test of Attentional Performance (TAP). This task is used as a language-independent alternative to the Stroop test in participants with aphasia or limited literacy. Performance is reported as a standardized score derived from error rates and reaction time measures, with higher scores indicating better response inhibition.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  28. TAP Alertness

    Non-lateralized attention domain: tonic alertness assessed using the Alertness subtest of the Test of Attentional Performance (TAP). Performance reflects baseline response readiness and is reported as a standardized score derived from reaction time measures, with higher scores indicating better alertness.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  29. TAP Divided Attention

    Non-lateralized attention domain: divided attention assessed using the Divided Attention subtest of the Test of Attentional Performance (TAP). Performance reflects the ability to allocate attentional resources across concurrent tasks and is reported as a standardized score derived from reaction time and/or error measures, with higher scores indicating better divided attention.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  30. TAP Shift of Focus

    Executive-attentional domain: attentional flexibility assessed using the Shift of Focus (Flexibility) subtest of the Test of Attentional Performance (TAP). Performance reflects the ability to shift attentional focus between task-relevant stimuli and is reported as a standardized score derived from reaction time and/or error measures, with higher scores indicating better attentional flexibility.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  31. Apples Test

    Lateralized attention domain: visuospatial attention bias assessed using the Apples Test, which dissociates egocentric and allocentric spatial attention deficits. Performance is reported using standardized asymmetry indices derived from cancellation accuracy, with greater symmetry indicating better spatial attention.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  32. Working Memory Questionnaire (WMQ)

    Working memory domain: Self-reported working-memory-related difficulties in everyday functioning assessed using a standardized Working Memory Questionnaire. Scores are reported according to the questionnaire scoring manual, with higher scores indicating greater perceived working-memory difficulties.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  33. Hospital Anxiety and Depression Scale (HADS)

    Depression and anxiety symptoms assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire with two 7-item subscales (Anxiety and Depression). Each item is scored 0-3; subscale scores range 0-21 and total score ranges 0-42, with higher scores indicating greater symptom severity.

    Time frame: From Baseline to follow-up assessments up to 15 months post-inclusion

  34. Fatigue Scale for Motor and Cognitive Functions (FSMC)

    Fatigue assessed using the Fatigue Scale for Motor and Cognitive Functions (FSMC), a 20-item self-report questionnaire comprising motor and cognitive fatigue subscales. Items are rated on an ordered response scale, and subscale and total scores are calculated according to the scoring manual, with higher scores indicating greater fatigue severity.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

  35. Modified Ashworth Scale (MAS)

    Spasticity assessed using the Modified Ashworth Scale (MAS) for specified joints (shoulder, elbow, wrist, hip, knee, ankle, fingers). MAS is scored on an ordinal scale (0, 1, 1+, 2, 3, 4), where higher scores indicate greater resistance to passive movement (greater spasticity).

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion.

  36. Muscle Strength Testing (MST)

    Voluntary muscle strength assessed using manual Muscle Strength Testing (MST) of upper and lower limbs according to standardized site procedures. Muscle strength is recorded as ordinal strength grades for predefined muscle groups of the upper and lower extremities, with higher grades indicating greater muscle strength.

    Time frame: From baseline to follow-up assessments up to 15 months post-inclusion

07

Study locations

3 of 5 sites recruiting
  • Lake Lucerne Institute
    Vitznau, Canton of Lucerne 6354, Switzerland
    Not yet recruiting
    • Christoph Bauer, PhD. · Contactchristoph.bauer@llui.org · +41 79 527 24 49
    • Christoph Bauer, PhD · Principal investigator
  • Klinik Valens
    Valens, Canton of St. Gallen 7317, Switzerland
    Recruiting
  • Centre hospitalier universitaire Vaudois
    Lausanne, Canton of Vaud 1011, Switzerland
    Recruiting
    • Olivier Bill · Contactolivier.bill@chuv.ch · +41 0213141260
    • Olivier Bill, MD · Principal investigator
  • Swiss Réhabilitation Sàrl
    Sullens, Canton of Vaud 1036, Switzerland
    Recruiting
  • Universitätspital Zürich
    Zurich, Canton of Zurich 8006, Switzerland
    Not yet recruiting
    • Andreas Luft, Prof. · Contactandreas.luft@usz.ch · +41 0798626436
    • Andreas Luft, Prof. · Principal investigator
08

References and documents

Publications

  • Sokolov AA, Serino A. SWISSNEUROREHAB - Technologie-assistiertes Continuum of Care in der Schweizer Neurorehabilitation. Neurol Rehabil. 2024;30(S1):28-29

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for May 2028, 27 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 27 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Feb 23, 2026
StartEst.
Feb 10, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07427511
Collaborators
Mindmaze SA, Innosuisse - Swiss Innovation Agency, Cereneo AG
Responsible party
Olivier Bill (MD, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Feb 23, 2026
Start date
Feb 10, 2026 (estimated)
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Mar 10, 2026

Study contacts

Olivier Bill, MD
Contact
olivier.bill@chuv.ch
+41 0213141260
Andrea Serino, Prof.
Contact
andrea.serino@chuv.ch
+41 21 314 3996
Andrea Serino, Prof.
study chair · Centre Hospitalier Universitaire Vaudois

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion